Novum Vitrium® Cervical Cage in Anterior Cervical Discectomy and Fusion

Safety and Effectiveness of Novum Vitrium® Cervical Cage in Anterior Cervical Discectomy and Fusion. A Randomized, Controlled, Non-inferiority, Pivotal Study

A prospective, multicenter, randomized, concurrently controlled, noninferiority clinical trial to compare the safety and effectiveness of instrumented Bio2 Vitrium Cervical Interbody Device in anterior cervical discectomy and fusion (ACDF) with structural allograft bone and local autologous bone graft in treating patients with a symptomatic degenerative cervical disc disease at one level from C3/C4 to C7/T1.

Study Overview

• Status: Terminated
• Conditions: Symptomatic Cervical Disc Disease
• Intervention / Treatment: Device: Novum Vitrium® Cervical Interbody Device; Device: Allograft Ring or Block

Detailed Description

The study will evaluate if Bio2 Vitrium® Cervical Interbody Device (VCIBD) is non-inferior to allograft cage in single-level ACDF with the use of local autologous bone. VCIBD is a restorable cervical interbody cage for the treatment of fusion, following discectomy, of the cervical spine from C3/C4 disc space to the C7/T1 disc space. The material used to manufacture the implant is 13-93 bioactive glass, which is a silicate-based material as described in ASTM F1538-03(R2017). The implant has high porosity and strength and does not contain any biological material or constitute a combination product. The device has a central lumen for packing with autograft. VCIBD is intended to be used with a supplemental fixation system.

The device, when placed between the vertebrae, provides mechanical stability and prevents subsidence prior to bone ingrowth. It restores and maintains the intervertebral space during the fusion process. The porosity and material characteristics provide an osteoconductive matrix that supports bone ingrowth. Additional stabilization is provided by supplemental fixation using anterior cervical plate. The implant incorporates a central lumen, which allows for the cage to be packed with autogenous bone graft.

• Study Type: Interventional
• Enrollment (Actual): 25
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • California
    • Orange, California, United States, 92868
      • Orthopaedic Education and Research Institute
  • Connecticut
    • Hartford, Connecticut, United States, 06102
      • Hartford Hospital
  • Indiana
    • Carmel, Indiana, United States, 46032
      • Indiana Spine Group
  • Kentucky
    • Paducah, Kentucky, United States, 42001
      • Orthopaedic Institute of Western Kentucky
  • New York
    • Syracuse, New York, United States, 13210
      • Upstate Medical University
  • North Carolina
    • Durham, North Carolina, United States, 27704
      • M3-Emerging Medical Research
  • Texas
    • Austin, Texas, United States, 78746
      • Arise Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 22 years to 70 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Symptomatic cervical disc disease (SCDD) in the one vertebral level between C3/C4 to C7/T1, defined as neck or arm (radicular) pain, or functional or neurological deficit and correlated with radiculopathy or myelopathy or radiographic confirmation (by CT, MRI, x-ray, etc.) of any of the following:

   • Herniated nucleus pulposus;
   • Spondylosis (defined by the presence of osteophytes); or
   • Loss of disc height.
2. Requires only one cervical vertebral level to be surgically treated, confirmed radiologically by Xray, CT, or MRI and correlated with neurologic examination prior to enrollment;
3. Age between 22 and 70 years (inclusive);
4. Skeletally mature patients;
5. Failed at least 6 weeks of conservative treatment (e.g. medication, physical therapy), or exhibit progressive symptoms or signs of spinal cord/nerve root compression with continued non-operative care;
6. Neck Disability Index (NDI) Questionnaire score of at least 30 (on a scale from 0 to 100);
7. Able to read and Understand all documents used in this study, including the Informed Consent and patient-reported outcome questionnaires;
8. Understand and read English at elementary level;
9. Patient must understand and sign the Informed Consent document that has been approved by the Ethics committee, Institutional review Board and the FDA.

Exclusion Criteria:

1. More than one vertebral level requiring treatment, confirmed radiologically by X-ray, CT, or MRI
2. Cervical instability;
3. Prior fusion surgery at any cervical vertebral level;
4. Prior surgery at the level to be treated with the exception of surgery that does not require the use of hardware and/or the treatment of facet disease;
5. Severe facet disease;
6. Clinically compromised vertebral bodies at the affected level(s) due to current or past trauma
7. Neck or arm pain of unknown etiology;

8. Osteoporosis, osteopenia, Paget's disease, osteomalacia or any other metabolic bone disease;

   a. Osteoporosis is defined as history of fragility fracture and Dexa (DXA) T-score < -2.5 or QCT T-score < 80mg/cubic cm. History of a fragility fracture requires that a DXA scan or QCT scan is completed

9. Pregnant or interested in becoming pregnant in the next 2 years;
10. Active systemic or local infection;
11. History of severe allergy or anaphylaxis especially to titanium, polyethylene, cobalt, chromium or molybdenum;
12. Taking medications or any drug known to potentially interfere with bone/soft tissue healing (e.g., steroids, bisphosphonates);
13. Rheumatoid arthritis or another autoimmune disease that affects musculoskeletal system;
14. Acquired immune deficiency syndrome (AIDS) or an AIDS-related complex;
15. Active malignancy or history of invasive malignancy within the last five years, except for superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitely treated; patients with carcinoma in situ of the uterine cervix treated definitely more than 1 year prior to enrollment may enter the study;
16. Neuromuscular disorders such as muscular dystrophy, spinal muscular atrophy, and amyotrophic lateral sclerosis;
17. Pre-existent neurologic or mental disorder which would preclude accurate evaluation and followup (i.e. Alzheimer's disease, Parkinson's disease, unstable psychiatric disorder with hallucinations and/or delusions or schizophrenia);
18. Substance use disorder categorized as moderate to severe as defined in DSM-V;
19. Mental/Psychiatric disorder as defined in DSM-V;
20. Alcohol abuse disorder categorized as moderate to severe as defined in DSM-V;
21. Current Smokers;
22. Use of bone growth stimulator in the region of the cervical spine within the past 30 days;
23. Participation in other investigational device or drug clinical trials within 30 days of surgery;
24. Prisoners;
25. Morbid obesity, defined as body mass index ("BMI") > 40;
26. Type 1 diabetes mellitus requiring daily insulin therapy unless there is documentation of a recent A1c (within 6 months) of less than 7.1 or Type 2 diabetes where the clinical presentation precludes the patient from having surgery;
27. Involved in litigation related to the spine;
28. On workers compensation

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: SINGLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: ACDF with Novum Vitrium® Cervical Interbody Device; A resorbable cervical interbody cage.	Device: Novum Vitrium® Cervical Interbody Device; For spinal fusion procedure at one level (C3 to T1) of the cervical spine.; Other Names: Novum Vitrium® Cervical Cage
ACTIVE_COMPARATOR: ACDF with Allograft; Structural allograft made from structural corticocancellous allograft bone.	Device: Allograft Ring or Block; Standard of Care

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants who have achieved of radiologic fusion assessed by roentgenographic examination.	Successful fusion is based on meeting the roentgenographic examination criteria showing the evidence of: bridging trabecular bone between the involved motion segments; translation motion <3mm; and angular motion ≤2°.	12 months
Change in Neck Disability Index (NDI) with a response greater than or equal to 15 from baseline.	NDI consists of ten items addressing function activities, pain intensity, concentration, and headache.It has a continuous various with a range from 0 (best) to 100 (worse). The effectiveness endpoint is the difference between the baseline value and the follow-up (12 month) value.	12 months
Number of participants with neurological success.	Neurological success is a binary outcome as follows: Maintenance or improvement of the neurological status;; Worsening of the neurological status. Worsening of the neurological status is defined as permanent new neurologic damage or permanent new nerve root injury related to the surgically treated level, defined as one or more: Permanent decrease in one or more grades of motor strength compared to baseline;; Permanent new sensory deficit (paresthesia or anesthesia) in a specific cervical nerve root distribution.	12 months
Number of participants who have completed follow-up up to month 12 without Secondary Surgical Intervention (SSI).	Identified as the absence of revision, removal, reoperation, or supplemental fixation at the index level	12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Measurement of Pain at neck and at arm and shoulder as assessed by Visual Analog Scale	Neck pain and arm/shoulder pain as measured by the Visual Analog Scale (VAS) on the scale from 0 (no pain) to 100 (worst imaginable pain)	6, 12, and 24 months
Quality of Life assessed by 36-Item Short Form Health Survey Version 2 (SF-36v2)	The SF-36v2 Health Survey is a 36-item instrument for measuring health status and outcomes. It yields an eight-scale profile score from the following eight health concepts: physical functioning, role limitations due to physical health problems, bodily pain, general health, vitality (energy/fatigue), social functioning, role limitations due to emotional problems, and general mental health (psychological distress and psychological well being). In addition, two composites scores are constructed using factorial modeling, one from physical health composite score (PCS) and one for mental health composite score (MCS).	6, 12, and 24 months
Quality of Life assessed by EuroQoL Health Related Quality of Life - 5 Dimensions - 3 Levels (EQ-5D-3L)	The EQ-5D-3L is a standardized instrument used as a measure of health outcomes. It contains questions in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and provides a simple descriptive profile and single index for health status preference. In addition, there is a Visual Analog Scale (VAS). The VAS is the participant's rating of their health on a scale of 0 "worst imaginable health state" to 100 "best imaginable health state".	6, 12, and 24 months
Measurement of the use of Pain Medication for Cervical Spine.	The use of prescription and OTC pain medication for cervical spine-related pain will be recorded in addition to the use of opioids on study-specific logs.	6, 12, and 24 months
Measurement of Patient Satisfaction: patients to rate their satisfaction	Developed based on IDE spine studies. It asks patients to rate their satisfaction with their treatment (6 choices from "Very Satisfied" to "Very Dissatisfied"), and question regarding every day activities and their ability to complete them. There are 5 choices from "Definitely" to "Definitely Not".	6, 12, and 24 months

Collaborators and Investigators

• Sponsor: Bio2 Technologies
• Collaborators: MCRA

Study record dates

Study Major Dates

• Study Start (ACTUAL): April 24, 2019
• Primary Completion (ACTUAL): March 21, 2022
• Study Completion (ACTUAL): March 21, 2022

Study Registration Dates

• First Submitted: January 25, 2019
• First Submitted That Met QC Criteria: January 31, 2019
• First Posted (ACTUAL): February 4, 2019

Study Record Updates

• Last Update Posted (ACTUAL): April 7, 2022
• Last Update Submitted That Met QC Criteria: March 30, 2022
• Last Verified: March 1, 2022

More Information

Terms related to this study

• Keywords: ACDF; Cervical Disc Disease; Single-level
• Additional Relevant MeSH Terms: Musculoskeletal Diseases; Pathological Conditions, Anatomical; Spinal Diseases; Bone Diseases; Hernia; Intervertebral Disc Displacement; Intervertebral Disc Degeneration
• Other Study ID Numbers: CT-17-001

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes